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ABSTRACT 
Objective: Tamoxifen (TAM) is a hormonal therapy that is clinically proven to reduce breast cancer recurrence by blocking estrogen receptor, 
mainly through its active metabolites, 4-hydroxytamoxifen (4HT) and endoxifen (END), which have a higher affinity to ER than TAM itself. The 
objective of the present study was to develop and validate simple and rapid LC-MS/MS method for analysis TAM and its metabolites simultaneously 
in dried blood spot (DBS) sample for monitoring studies purposes.  
Methods: Optimization was done by evaluating several parameters that affect the efficiency of DBS preparation, such as blood spot volume, drying 
time and extraction method from the DBS paper. The effectiveness of chromatographic conditions was also optimized by varying flow rate, mobile 
phase combination and gradient. Clomiphene was used as the internal standard.  
Results: The result showed that preparation of 20 µl blood spot volume with 120 min of drying time and 25 min of extraction time using 1 ml 
methanol was the most efficient condition and also fulfilled recovery and matrix effect requirement according to FDA and EMA guidelines. The 
separation was performed on UPLC Class BEH C18 using formic acid 0.1%-formic acid 0.1% in acetonitrile (35:65) as the mobile phase in isocratic 
mode at 0.25 ml/min with a total analysis time of 4 min. 
Conclusion: This method has successfully fulfilled all validation requirements referring to EMA and FDA guidelines. 
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INTRODUCTION 
Tamoxifen (TAM) is a hormonal therapy that is given to 
premenopausal patients with estrogen receptor-positive type of breast 
cancer. TAM treatment for 5 y after surgery has been proven to reduce 
the recurrence rate of ER+breast cancer by 50% in treatment five 
years after surgery and reduce the 30% mortality rate [1, 2]. TAM is a 
prodrug that go through metabolism in hepatic mediated by 
cytochrome P450 enzyme via N-demethylation followed by 4-
hydroxylation. Demethylation product of tamoxifen via CYP3A4, 
namely N-desmetyltamoxifen (NDT) is the most abundant metabolite 
but not active to estrogen receptors. NDT then metabolized to 4-
hydroxy-N-desmethyltamoxifen or Endoxifen (END) mediated by 
CYP2D6. There are also other metabolic pathways through 
hydroxylation of tamoxifen to 4-hydroxytamoxifen (4HT). This 
pathway is mediated not only by CYP2D6 but also by CYP3A4 and 
CYP2C19. However, this pathway is classified as minor [3]. 
TAM is clinically proven to reduce breast cancer recurrence by 
antagonist action of its active metabolite, END, and 4HT to the 
estrogen receptor. Those two metabolites have a higher affinity to 
the estrogen receptor than TAM itself [4]. END shows more potent 
antiestrogenic activity, about 100fold more potent than TAM. 
Compared to 4HT, END shows higher plasma concentrations than 
4HT, thus make END become a surrogate endpoint for tamoxifen 
therapeutical monitoring. Two large retrospective studies, 
conducted by Madlensky and Saladores have shown a correlation 
between END level and disease-free survival in patients with early 
breast cancer treated with tamoxifen have shown a positive 
relationship between the availability of END in the blood and 
disease-free survival rates in early breast cancer patients treated 
with tamoxifen [5, 6]. Madlensky declared 5.97 ng/ml as the 
threshold, while Saladores stated the level of 15 nmol/l was the 
threshold at which patients with levels below that had worse results 
compared to those with higher levels. However, these END levels 
showed high variability between patients, widely based on CYP2D6 
genetic polymorphism status [7, 8]. The need for an effective and 
efficient bioanalytical method that also provides fast and reliable 
sample preparation is essential to determine TAM and its active 
metabolites, in order to do TAM therapeutical drug monitoring.  
Several previous studies have published the analysis method of TAM 
and its metabolites in serum and plasma biosamples using the HPLC 
and also LC-MS/MS. [9-12]. Recently, Dried Blood Spot (DBS) has 
become a prominent alternative bio sampling for therapeutic drug 
monitoring. Different from the conventional venipuncture method; 
the DBS method collected the blood from a finger prick. This 
procedure is less invasive than venipuncture, thus more convenient 
and straightforward with better patient comfort. DBS also 
guarantees higher stability of the analyte and is easier to transport 
from the sampling site to the test laboratory [13]. However, the 
concern that arises from DBS is the small volume of blood samples, 
which results in fewer levels than in plasma and serum. Therefore, a 
more sensitive analysis technique is required. In this study, we 
focused on developing a simple and also sensitive method for TAM, 
END, and 4HT analysis using LC-MS/MS system with clomiphene 
(CLO) as an internal standard. Optimization was done by evaluating 
several parameters that affect the efficiency of DBS preparation, 
such as blood spot volume, drying time, and extraction method from 
the DBS paper. The effectiveness of chromatographic conditions was 
also optimized by varying flow rate, mobile phase combination, and 
gradient.  
MATERIALS AND METHODS 
Methods 
Reference standard samples and materials 
END E/Z mixture and 4HT were bought from Santa Cruz 
Biotechnology (USA), while TAM was obtained from Sigma-Aldrich 
(Singapore). Clomiphene (CLO) as the internal standard was 
purchased from Fabbrica Italiana Sintetici (Italy). Chemical reagent 
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and solvent to be used in this research, such as acetonitrile HPLC 
grade, Formic acid, and methanol were obtained from Merck 
(Germany). DBS card used in this research was Perkin Elmer 226 
paper obtained from PerkinElmer (USA), and whole blood for 
validation was obtained from the Indonesian Red Cross. 
Instrumentation 
Chromatography system was using the UPLC C-18 BEH Acquity 
column with dimension 2.1 x 100 mm and particle size of 1.7 μm. 
Column temperature was set at 30 °C. LC-MS/MS system was using 
Waters Xevo Triple Quadrupole. The MS system is controlled by 
MassLynx Software Waters (Milford, USA). Multiple reaction 
monitoring (MRM) chromatograms in the positive ion electrospray 
ionization mode were used in this system. Mass transitions of m/z 
were optimized for TAM, END, 4HT and CLO by infusion of the 
respective analytes in methanol. MS settings for capillary voltage, 
desolvation gas, cone voltage and collision refers to a previous study 
[14], the data are shown in table 1. 
 
Table 1: ESI MS/MS operating parameter 
Analyte Fragment (m/z) Capillary (kV) Desolvation gas Cone (V) Collision (V) 
   Temp (°C) Rate (L/h)   
TAM 372.2>72.27 3.50 350 650 50 27 
END 374.29>58.2 45 30 
4HT 388.29>72.19 50 27 
CLO 402>100.17 45 25 
 
Calibration standard and quality control (QC) sample 
Quality control (QC) solution and calibration sample were prepared 
from a separate stock solution. The preparation of the stock solution 
and working solution of analytes and internal standard followed the 
previous method with modification [14, 15]. Stock solutions were 
prepared by diluting analyte in methanol (1,000 ng/ml). 
Intermediate solution was made by diluting the stock solution (100 
ng/ml). This intermediate solution was diluted to obtain a working 
solution. Calibration samples must be freshly prepared for every run 
in whole blood by diluting working solutions with whole blood 
blank. Clomiphene (CLO), Internal standard stock solution was 
prepared in methanol (1000 ng/ml).  
Optimization of chromatographic condition 
Mobile phase was optimized using four combinations of formic acid, 
methanol and acetonitrile (table 2). 
The elution system was optimized in gradient and isocratic elution. 
Flow rate was also optimized to obtain efficient analysis time in the 
range of 0.1-0.3 ml/min. System suitability test was conducted using 
optimum analysis condition. 
 
Table 2: Combination of mobile phase 
A B 
Formic Acid 0.1% Formic acid 0.1% in methanol 
Formic Acid 0.2% Formic acid 0.2% in acetonitrile 
Formic Acid 0.1% Acetonitrile 
Formic Acid 0.1% Formic acid 0.1% in acetonitrile 
 
Optimization of sample pretreatment and extraction process 
The pretreatment and extraction sample process refer to Antunes, et al., 
with optimization at several stages. Optimizations carried out at the 
pretreatment stage include the volume of blood collection, drying time 
and sonication time. Blood from the finger prick was collected in a 
microtube and pipetted with a micropipette to obtain a quantitative 
sample volume. The blood volume was varied 10, 20 and 30 µl. The 
optimum volume was then spotted on DBS paper and dried. Drying time 
was varied at 30 min, 1 h, and 2 h. Tests were carried out at (Lower Limit 
of Quantification) LLOQ and Upper Limit of Quantification (ULOQ) 
concentrations. Observations were made by comparing retention times 
and areas of the three variations. The spotting volume which gives the 
best results is continued at the validation stage 
Optimization at the extraction stage was carried out at sonication 
time, which varied in 25, 30, and 45 min. 100 μl whole blood 
containing 0.1% clomiphene and 1000 μl methanol as an extraction 
solvent was added to the cut DBS in a tube. 850 μl of the sample 
mixture was dried under nitrogen with a temperature of 55 °C for 15 
min, and the dried extract was then dissolved in the mobile phase. 
The sample mixture in the mobile phase was centrifuged for 10 min 
at 3000 rpm. The supernatant was poured to an autosampler vial. 10 
μl of the sample was injected onto the LC-MS/MS system [14, 15] 
Validation assay 
Full validation assay was performed according to the Food and Drug 
Administration (FDA) (2018) and the European Medicines Agency 
(EMA) (2011) guidelines for bioanalytical method validation [16, 17].  
Selectivity 
The selectivity test is carried out to test the ability of the bioanalysis 
method to distinguish analytes and internal standards from 
endogenous components in the matrix. The selectivity test used 
whole blank blood from six different sources, each analyzed and 
compared for interference. The existence of confounding 
components can still be accepted if the response obtained does not 
exceed 20% of the LLOQ in the analyte and does not exceed 5% of 
the internal standard. 
Linearity 
Calibration curves were made by plotting the peak area ratio 
(PAR) against the standard calibration concentration in a whole 
blood stimulation. PAR is a comparison between analytes 
responses compared with IS responses. Calibration level for TAM 
ranged between 5-200 ng/ml; END 1-40 ng/ml, and 4-HT 0.5-20 
ng/ml. The acceptance criteria for each concentration on average 
must not exceed±15% deviation from the nominal value and±20% 
for LLOQ.  
Accuracy and precision  
Within run and between run assay for determining accuracy and 
precision was carried out from 5 replicates of quality control 
solution in LLOQ, QCL, QCM and QCH level. The % CV and %diff for 
each concentration must not exceed 15%, except LLOQ is not exceed 
20%  
Recovery 
This test aims to determine the extraction efficiency of the TAM, 
END and 4-HT and IS from the DBS sample. Recovery test was 
performed by comparing the response of analytes extracted from 
three replicates of QCL, QCM and QCH samples, with a neat standard 
solution. Recovery of the analyte need not be 100%, but must be 
consistent, precise, and reproducible (15% for the %CV value). 
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Carry-over 
Samples in the blank, LLOQ, and ULOQ concentrations containing 
TAM, END, and 4HT were extracted and injected to the LC-MS/MS 
system by following these steps: LLOQ, ULOQ, and blank. The 
acceptance criteria established for the carry-over is a maximum of 
20% for the % carry-over. 
Dilution integrity 
Standard solutions of TAM, END, and 4HT were diluted in whole 
blood to obtain the concentration above the ULOQ concentration, 
precisely at twice the QCH concentration. Furthermore, the solution 
was reconstituted until half of the concentration and a quarter of the 
concentration is obtained. The assay was performed with five 
replicates for each concentration. Dilution shall not affect accuracy 
and precision if the %diff and %CV value are not above 15%. 
Stability 
a. Standard solution stability 
Standard solutions of TAM, END, 4HT, and CLO with a concentration of 
1000 μg/ml was injected one by one into the LC-MS/MS system as 
described above. The short term stability tests were carried out at 0, 6, 
and 24 h after storing the standard solutions at room temperature. 
The long term stability tests were carried out at 0 and 20 d after 
storing the standard solutions in the freezer (-20 °C). The assays were 
performed with two replicates. The acceptance criteria established for 
the stock solution stability is a maximum of 10% for the %diff value.  
b. Short term stability in DBS 
Standard solutions of TAM, END, and 4HT were diluted in whole 
blood to obtain QCL and QCH concentration, then extracted and 
injected into the LC-MS/MS system. The short term stability tests in 
DBS were carried out at 0, 6, and 24 h after storing the standard 
solutions at room temperature before being analyzed. The assays 
were performed with three replicates. The acceptance criteria 
established for the short term stability in DBS is a maximum of 15% 
for the %diff and %CV value. 
c. Long term stability in DBS 
Standard solutions of TAM, END, and 4HT were diluted in whole 
blood to obtain QCL and QCH concentration, then extracted and 
injected into the LC-MS/MS system. The long term stability tests in 
DBS were carried out at 0 and 20 d after storing the standard 
solutions in the refrigerator (4 °C) before being analyzed. The assays 
were performed with three replicates. The acceptance criteria 
established for the short term stability in DBS is a maximum of 15% 
for the %diff and % CV value. 
d. Autosampler stability 
Standard solutions of TAM, END, and 4HT were diluted in whole 
blood to obtain QCL and QCH concentration, then extracted and 
injected into the LC-MS/MS system. The analysis was carried out at 
0 and 24 h after storing the sample in the autosampler before being 
analyzed. The assays were performed with three replicates. The 
acceptance criteria established for the short term stability in DBS is 
a maximum of 15% for the %diff and %CV value. 
RESULTS AND DISCUSSION 
Optimization of sample volume 
The sample volume was optimized in the range of 10-30 µl to obtain 
the lowest volume for patient convenience. Blood then spotted in 
Perkin Elmer 226 and dried at room temperature. Sample was 
prepared then analyzed with the optimum chromatographic 
condition. The results showed that more sample volume could 
increase the analyte area, but no effect showed in retention time. 20 
µl was chosen as the optimum volume considering patient 
convenience. 50 and 60 µl as reported in the previous study, was too 
much to obtain from a finger prick and eventually painful for the 
patient. 20 µl sample spot showed an adequate area of 
chromatograms as 30 µl spot and also proven to give adequate 
recovery and LLOQ. This study shows that the application of this 
method will be more convenient for patients, compared to the study 
of Antunes et al. (2014) which required 60 µl and Tré-Hardy et al. 
(2016) which required 50 µl for the sample volume [15, 18] (fig. 1). 
 
 
Fig. 1: Optimization sample spot volume of DBS and its influence to area chromatograms of TAM, END and 4HT 
 
Optimization of drying time  
Drying time was optimized in the range of 30 min to 2 h. The sample 
was dried at 25 °C for 30 min, 1 h, and 2 h. The results showed that 
30 min and 1 h were too short for drying the sample because of 
those resulted in small analyte area and unstable chromatograms. 
Meanwhile, dry the sample for 2 h resulted in a more stable 
chromatogram than the others. This concluded that 2 h is the most 
suitable drying time for this study. Optimization of blood sample 
drying time has also been done previously by Koster et al. in 
2015.[19] The drying time of the DBS sample affects the area of 
chromatograms and recovery. In this study, drying time up to 2 h 
was adequate to give a functional area of chromatograms. We did 
not conduct a longer drying time since 2 h was already fulfilled all 
validation parameter criteria and also due to analysis efficiency. 
Based on the results of these studies, it can be concluded that the 
drying time of blood samples can affect the area produced and affect 
recovery parameters in the study (fig. 2). 
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Fig. 2: Optimization of drying time of DBS and its influence to area chromatograms of TAM, END and 4HT 
 
Optimization of extraction solvent volume 
The volume of the extraction solvent was optimized in the range of 
500-1000 µl. Based on the test results obtained, an increase in the 
volume of the extracting solution causes an increase in the area of 
the analyte. The test results showed that there is a significant 
difference in the area of the analyte produced. The volume of 1000 
μl showed the highest area that indicates a good recovery (fig. 3). 
 
 
Fig. 3: Optimization of extraction solvent volume and its influence to area chromatograms of TAM, END and 4HT 
 
 
Fig. 4: Optimization of sonication time and its influence to area chromatograms of TAM, END and 4HT 
Harahap et al. 
Int J App Pharm, Vol 12, Issue 3, 2020, 112-120 
116 
Optimization of sonication time 
The sonication time was optimized in the range of 25-45 min to 
obtain a good chromatogram in a possibly shortest time. The results 
indicated an increase in the duration of sonication time could cause 
a decrease in area, and the chromatogram was not well separated. 
25 min was chosen as the optimum sonication time because it gave 
the highest analyte area in the shortest time (fig. 4). 
Optimization of sample analysis 
Based on the results obtained, the retention time generated from the 
four mobile phase combinations has no significant difference. The 
combination of 0.1% formic acid with 0.1% formic acid in 
acetonitrile (35:65) was chosen as the most optimum combination 
of the mobile phase because it produced a better area of analyte and 
internal standard with a better chromatogram than other mobile 
phase combinations. When compared with the results of the elution 
using the gradient elution method, the shape of the chromatogram 
produced in the analysis with the isocratic method is better, where 
the peak of the four components can be adequately separated, and 
the resulting peak shape does not experience tailings and fronting as 
shown in fig. 5. In addition, the retention time produced in the 
analysis with the isocratic method at 35:65 composition was also 
faster than that of gradient elution. Therefore, the isocratic method 
with a composition of 35:65 was chosen as the elution method in 
this analysis. When compared with other previous studies using the 
gradient elution method, this elution method is simpler because the 
mobile phase composition does not change during the analysis 
process, and the analysis time is shorter (fig. 5). The result of system 
suitability tests was summarized in table 3. 
 
 
Fig. 5: Chromatogram obtained with 0.1% formic acid formic acid 0.1 % formic acid in acetonitrile (35:65) at 0.25 ml/min 
 
Table 3: Result of the system suitability test 
Parameter TAM END 4HT CLO 
%CV of Area  1.9 4.27 4.72 0.88 
%CV of Retention time 1.49 0.47 1.36 1.59 
CV: Coefficient Variation. number of experiments (n): 5 
 
 
Fig. 6: TAM calibration curve 
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Validation assay 
The linearity of the calibration curve was shown for TAM over the 
range of 5.0-200.0 ng/ml; 1.0-40.0 ng/ml for END; and 0.5-20.0 
ng/ml for 4HT with a correlation coefficient of 0.99 for those three 
compounds. The LLOQ for TAM was 5.0 ng/ml; END was 1.0 ng/ml; 
and 4HT 0.5 ng/ml with a %CV less than 20% (fig. 6-8). The 
resulting calibration curve can be stated linearly and meets the 
requirements, % diff not more than 15% at all concentrations other 
than LLOQ and no more than 20% at LLOQ concentrations. 
 
 
Fig. 7: END calibration curve 
 
 
Fig. 8: 4HT calibration curve 
 
The selectivity assay gave the results over the % interference range of 
0.11-9.07% for TAM; 0.80-13.77% for END; 2.09-13.73% for 4HT; and 
0.18-0.63% for CLO. These results indicate that the analytical method 
developed can selectively analyze TAM, END, 4HT and CLO in a matrix 
and able to distinguish analytes and internal standards from endogenous 
components in the matrix or other components in the sample (table 4). 
 
Table 4: Result of selectivity 
Analyte Conc. (ng/ml) % interference 
TAM  5.00 9.07 
END 1.00 13.77 
4HT 0.50 13.73 
CLO 100 -0.63 
Number of experiments (n): 6 
 
Within run and between run Accuracy and precision tests were 
performed at LLOQ, QCL, QCM, and QCH concentration levels. The 
accuracy (%diff value) TAM, END, and 4 HT were less than 20%. The 
precision (%CV value) for the within run and between run of TAM, 
END and 4HT respectively was 4.02-7.44%; 3.56-9.32% and 4.65-
10.82% (14).  
Recovery was calculated using three replicates at three 
concentration levels: QCL, QCM, and QCH. The mean recovery 
(%recovery value) for TAM, END, and 4HT was 91.46%; 86.57%; 
and 78.89% with %CV value less than 15% for all compounds. The 
results showed that the method is reliable within the analytical 
range (table 5). 
Harahap et al. 
Int J App Pharm, Vol 12, Issue 3, 2020, 112-120 
118 
Table 5: Result of recovery 
Analyte Conc. (ng/ml) Recovery 
  (% Recovery) (%CV) 
TAM 25.00 85.51 5.97 
 75.00 93.08 
 150.00 95.77 
END 5.00 84.21 7.12 
 15.00 90.92 
 30.00 84.58 
4HT 2.50 81.22 11.29 
 7.50 84.38 
 15.00 71.08 
CLO  84.68 2.81 
CV: Coefficient variation. number of experiments (n): 3 
 
The carry-over value was calculated after the injection of a high 
concentration (ULOQ) sample. The carry-over value range of TAM 
was 0.02-9.22%; 2.61-15.97% for END; 1.00-17.65% for 4HT; and 
0.01-0.03% for clomiphene. Those values met the requirement for 
an analyte area at the LLOQ (no more than 20%) and 5% for IS. The 
results showed no carry-over effect in the blank sample after 
injecting the highest concentration (ULOQ).  
Dilution is one of the steps carried out to obtain standard 
working solutions and sample preparation. Therefore, it is 
necessary to ensure that dilution does not affect accuracy and 
precision. The %CV for TAM, END, and 4HT was less than 15%. 
The results showed that the dilution of ULOQ sample with a 
blank matrix did not affect the accuracy and precision of the 
bioanalysis (table 6). 
  
Table 6: Result of dilution integrity 
Analyte Conc. (ng/ml) Result (ng/ml) Precision (%CV) Accuracy (%diff) 
TAM 300 298.84±10.31 3.45 -4.39 
 150 148.26±5.67 3.82 -7.03 
 75 71.65±4.74 6.62 -10.91 
END 60 59.33±4.61 7.77 10.30 
 30 28.57±2.10 7.35 -11.20 
 15 14.72±0.72 4.91 -7.64 
4HT 30 31.19±2.40 7.70 13.15 
 15 14.07±0.69 4.91 -10.51 
 7.5 7.40±0.79 10.65 12.60 
CV: Coefficient variation. number of experiments (n): 3 
 
The standard solution stability test showed that TAM, END, 4HT, and 
CLO standard solutions were stable at room temperature for 24 h 
(short term stability) and in the freezer (-20 °C) for 20 d (long term 
stability). The stability test for TAM, END, and 4HT in DBS was 
evaluated under short and long term in storage temperature and 
autosampler condition prior to analysis. The stability showed that 
TAM, END, and 4HT were stable at room temperature for 24 h, at 24 
h in the autosampler, and AT room temperature for 20 d. The %CV 
of TAM, END, 4HT, and CLO was less than 15%. The summary of 
stability test results are listed in table 7. 
 
Table 7: Stability data 
Analyte Stability Actual Conc. (ng/ml) Concentration change (%) Precision Accuracy 
    (%CV) (%diff) 
TAM Short term 25.00 -0.84 4.27 -4.49 
  150.00 -0.24 4.73 -5,59 
 Long Term 25.00 1.28 5.40 6.93 
  150.00 0.50 3.25 3.07 
 Autosampler 25.00 -3.70 2.15 -6.54 
  150.00 -4.57 2.80 -4.59 
END Short term 5.00 3.72 5.04 -5.47 
  30.00 -1.11 5.93 -9.01 
 Long Term 5.00 -2.48 7.12 -12.58 
  30.00 2.70 3.02 3.67 
 Autosampler 5.00 -4.38 5.43 -8.41 
  30.00 -4.70 2.27 -9.11 
4HT Short term 2.50 -4.76 7.29 -11.88 
  15.00 -2.92 6.39 -9.84 
 Long Term 2.50 -4.36 8.55 -12.79 
  15.00 0.86 8.48 10.98 
 Autosampler 2.50 -7.69 4.74 -6.87 
  15.00 -5.90 5.10 -9.62 
CV: coefficient variation number of experiments (n): 3 
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DISCUSSION 
We have developed the UPLC–MS/MS method to analyze TAM and 
its primary metabolites, END and 4HT in DBS biosample. During 
method development, the effect of sample volume, extraction 
solvent, and sonication time was tested in combination with 4 types 
of mobile phase and elution mode. The detector response was 
recorded to observe the effect of each variable. The result showed 
that we had developed a simple preparation technique that requires 
only a single step and fast extraction using methanol. The effect of 
sonication time to detector response was tested from 25 min to 45 
min, as reported by Jager, et al. that 45 min gave the best response 
[20]. Our result showed that 25 min has no significance different to 
45 min of sonication. Further recovery examination was conducted 
and proved that 25 min of sonication gave sufficient recovery and 
fulfilled precision and accuracy requirements.  
The method allows simultaneous analysis of TAM, END, and 4HT 
with a total analysis time of 4 min that is obtained by isocratic 
elution. The low LLOQ values indicates selective and sensitive 
techniques in order to evaluate the low dose of TAM. We obtained a 
limit of quantification for END at 1 ng/ml and for 4HT at 0.5 ng/ml. 
The same result also reported by Antunes et al., 2014 but our 
method used a smaller volume of blood spot. This DBS biosampling 
method requires an only small amount of blood, 20 µl, to provide 
patients convenience.  
Extraction recoveries ranged from 71.08% to 95.77% were 
consistent with an acceptable CV within 15%, including IS recovery. 
Consistent retrieval values at low and high concentration show that 
throughout this concentration range, the extraction method is 
acceptable. The DBS samples used in the bioanalytical validation was 
obtained from venous blood, for practical reasons, while the clinical 
samples were derivative from capillary blood, the concentration of 
these two matrices was earlier revealed to vary, largely due to 
slower distribution equilibrium in the capillaries[21]. To overcome 
this problem, sampling should be performed in a steady state level 
in the next clinical application trial, to ensure that the drug has 
already been distributed. 
CONCLUSION 
In conclusion, a rapid, sensitive and easier technique for DBS TAM, 
END and 4HT quantification with UPLC-MS/MS have been 
developed and validated. The analytical performance was similar to 
those outlined in prior technique but with a shorter run time of 6 
min, the smallest spot volume of 20 μl, a single solvent extraction 
process, and 25 min of sonication. Sensitivity and recovery were also 
maintained and sufficient enough for quantification of TAM, END, 
and 4HT in the patient, even though with low spot volume. This 
method has successfully fulfilled all validation requirements 
referring to EMA and FDA guidelines. However, further clinical 
investigations in the patient should be conducted to fully validated 
the method and assure its applicability for routine drug monitoring.  
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